ACTG
A5240 (Opening
Soon)
Study Drugs
All participants will be vaccinated with the quadrivalent human papillomavirus
recombinant vaccine (0.5 mL, GARDASILl) by injection at day 0 and weeks 8
and 24.
Eligibility
Criteria
Women
only
Contact
Beverly
Putnam, RN, ANP (303) 724-0762
BACK
Return
to HOME
